Tinka Haydn

Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis

Sarah Kehr, Tinka Haydn, Annika Bierbrauer et al. · Cancer Letters · 2020 · 59 citations

Pediatric Cancer, Medicine, Apoptosis +9

Concomitant epigenetic targeting of LSD1 and HDAC synergistically induces mitochondrial apoptosis in rhabdomyosarcoma cells

Tinka Haydn, Eric Metzger, Roland Schuele et al. · Cell Death and Disease · 2017 · 57 citations · Full text

Structure-activity studies on N -Substituted tranylcypromine derivatives lead to selective inhibitors of lysine specific demethylase 1 (LSD1) and potent inducers of leukemic cell differentiation

Johannes Schulz‐Fincke, Mirjam Hau, Jessica Barth et al. · European Journal of Medicinal Chemistry · 2017 · 36 citations · Full text

Tranylcypromine Derivatives, Drug Target, Medicine +11

BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis

Ulrike Heinicke, Tinka Haydn, Sarah Kehr et al. · Oncogene · 2018 · 30 citations

Tumor Biology, Oncology, Oncogenic Agent +10

Next-generation hypomethylating agent SGI-110 primes acute myeloid leukemia cells to IAP antagonist by activating extrinsic and intrinsic apoptosis pathways

Jessica Dittmann, Tinka Haydn, Patrick Metzger et al. · Cell Death and Differentiation · 2019 · 28 citations · Full text

Hematological Malignancy, Medicine, Malignant Blood Disorder +9